Q-omics provides the consensus-scored VPREB3 profile across patient tissues and cancer cell-line models. VPREB3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, VPREB3 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, VPREB3 RNA expression shows 13,103 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, COAD, and TGCT as cancer lineages where VPREB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPREB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPREB3 survival associations across molecular data types. VPREB3 RNA expression shows survival associations in the most cancer types (20), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPREB3 RNA expression–survival associations across cancer types. High VPREB3 expression shows unfavorable associations in ACC and LGG, but favorable associations in HNSC, ESCA, SKCM and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for VPREB3 RNA expression.
This table summarizes VPREB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for VPREB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPREB3 shows lower tumor expression in COAD, BLCA and THCA and higher tumor expression in LUAD, UCEC and BRCA. The COAD box plot shows higher VPREB3 RNA expression in normal versus tumor tissue (log2 FC = −2.202, t-test p < 0.001).
This table shows molecular features associated with VPREB3 in patient tissues and cancer cell lines. In patient samples, VPREB3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, VPREB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
